Webcast Details for Cassava Sciences’ Upcoming Fireside Chat

Rhea-AI Summary

Cassava Sciences, Inc. (Nasdaq: SAVA) will hold a webcast on April 5, 2022, at 9 AM ET, featuring President & CEO Remi Barbier and CFO Eric Schoen. Stakeholders are invited to listen via the provided webcast link. Although there will be no live Q&A, participants can submit questions beforehand via email. The event will also have an archived replay available on the company's website for 90 days. Cassava focuses on developing treatments for Alzheimer’s disease, particularly their lead drug candidate, simufilam, currently in Phase 3 clinical trials.

Positive

• Cassava is advancing its lead drug candidate, simufilam, in Phase 3 clinical trials, indicating progress in Alzheimer’s treatment.
• The upcoming webcast presents an opportunity for investor engagement and transparency regarding company developments.

Negative

• None.

– All Stakeholder Are Welcome to Listen by Webcast –

– Event To Be Held Tuesday, April 5^th, 9am ET –

AUSTIN, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer. This event is scheduled to take place on Tuesday, April 5^th at 9am Eastern time.

All stakeholders are welcome to listen by webcast. The link to join this webcast is:
https://onlinexperiences.com/Launch/QReg/ShowUUID=BA75442A-4327-4876-92D5-C3E6CD20BF79

There will be no live question-and-answer session during the fireside chat, however, prior to the event, stakeholders are encouraged to submit questions or comments for management’s consideration via email: SAVAquestionsQ1@CassavaSciences.com

Management may not be able to address all comments or questions due to SEC Regulation Fair Disclosure (FD), limits around legal disclosures, time constraints or other limitations.

An archived replay of this event will be available on Cassava Sciences’ website www.CassavaSciences.com in the ‘Investors’ section for approximately 90 days following the event.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer’s disease, in Phase 3 clinical studies under Special Protocol Assessments from the FDA. Simufilam is also being tested in an open-label study and a randomized, double-blind, placebo-controlled Cognition Maintenance Study in patients with Alzheimer’s disease.

For more information, please visit: https://www.CassavaSciences.com   

For More Information Contact:
Eric Schoen, Chief Financial Officer
ESchoen@CassavaSciences.com
(512) 501-2450

FAQ

When is Cassava Sciences' upcoming webcast event?

The upcoming webcast event is scheduled for April 5, 2022, at 9 AM ET.

Who will be presenting during the Cassava Sciences webcast?

President & CEO Remi Barbier and CFO Eric Schoen will present during the webcast.

How can stakeholders participate in the Cassava Sciences webcast?

Stakeholders can join the webcast by accessing the provided link in the press release.

Will there be a live Q&A session at the Cassava Sciences webcast?

No, there will not be a live question-and-answer session during the webcast.

Where can I find the archived replay of the Cassava Sciences webcast?

The archived replay will be available on Cassava Sciences' website in the 'Investors' section for approximately 90 days.